Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Andy Rawstron, PhD, Claudia Fazi, PhD, Neus Villamor, MD PhD, Julio Delgado, MD PhD, Remi Letestu, MD PhD, Florence Cymbalista, MD, Carlos Palacio, Francesc Bosch, MD PhD, Ruth M De Tute, MSc, Stuart Liptrot, David O'Brien, FAMLs, Martin Spacek, MD, PhD, Johan Dobber, Arnon P. Kater, MD PhD, Peter C Gambell, David A Westerman, MBBS, FRACP, FRCPA, Asha Soosapilla, Stephen P. Mulligan, MBBS, PhD FRACP, FRCPA, Gerard Lozanski, MD, Ke Lin, PhD, Andrew R Pettitt, MRCP, PhD, Gabi Brachtl, Alexander Egle, MD, David W Williamson, PhD, Catherine M Sanders, PhD, Harlan Robins, PhD, Justin Boysen, Tait D. Shanafelt, MD, Curtis A. Hanson, MD, Jeffrey L. Jorgensen, MD PhD, William G. Wierda, MD PhD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Laura Rassenti, PhD, H. Elizabeth Broome, MD, Thomas J. Kipps, MD PhD, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, MBBS, Nomdedeu Josep, Carol Moreno, MD, Olga Stehlikova, MSc., Michael Doubek, Sarka Pospisilova, Prof., Dr., PhD, Karl-Anton Kreuzer, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Emili Montserrat, MD PhD, Paolo Ghia, MD

Blood (2014) 124 (21): 1976.

https://doi.org/10.1182/blood.V124.21.1976.1976

Published: 2014

Journal Articles

MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162

O. Giles Best, BSc, PhD, Kyle Crassini, William s Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2013) 122 (21): 4192.

https://doi.org/10.1182/blood.V122.21.4192.4192

Published: 2013

Journal Articles

Genomic Profiling In Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (ALLG CLL5 OFOCIR trial) As Initial Treatment Of Chronic Lymphocytic Leukemia (CLL)

XAVIER BADOUX, MBBS FRACP FRCPA, Giles Best, BSc (Hons) Ph.D., Sara Gabrielli, Miss, Ying Zhu, PhD, Melanie Hayes, PhD, Bryone J Kuss, MBBS, PhD, FRCPA, William Stevenson, MBBS, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2013) 122 (21): 1624.

https://doi.org/10.1182/blood.V122.21.1624.1624

Published: 2013

Journal Articles

The Prevalence of Monoclonal B-Lymphocytosis in Individuals Aged 90 to >100 Years Is 10% with More Non-CLL Than CLL-Like Clones

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Asha Soosapilla, Carmela Brizzi, Christopher S. Mulligan, MB BS, BA, Nenna van Bilsen

Blood (2012) 120 (21): 4569.

https://doi.org/10.1182/blood.V120.21.4569.4569

Published: 2012

Journal Articles

Inhibition of Mitogen Activated Protein Kinase Kinase (MEK1) Is Effective Against CLL Cells Cultured in Media Alone or in a Supportive Microenvironment and Is Synergistic with Fludarabine in a Mechanism That Involves Decreased Levels of Reactive Oxygen Species and MCL-1 Protein

Giles Best, BSc (Hons) Ph.D., Kyle Crassini, Williams Stevenson, MBBS, PhD, Stephen P. Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2012) 120 (21): 1804.

https://doi.org/10.1182/blood.V120.21.1804.1804

Published: 2012

Journal Articles

A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MB ChB, MRCP (UK), FRCPath (Lond), Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MB ChB, FRACP, FRCPA, David Simpson, FRACP, FRCPA, MBChB, Philip Campbell, MBBS, FRACP, FRCPA, Campbell Tiley, MBBS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Marnie Collins, BCom, BSc(Hons), Paul Cortissos, Melanie Sulda, B.Sc, Ph.D., Giles Best, B.Sc., Ph.D., Bryone J Kuss, MBBS, PhD, FRCPA, FRACP

Blood (2012) 120 (21): 436.

https://doi.org/10.1182/blood.V120.21.436.436

Published: 2012

Journal Articles

The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.

Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA, Devinder S Gill, MD, William E. P. Renwick, MBBS, FRACP, Melanie L Sulda, BSc, Ph.D, O. Giles Best, BSc, PhD, Bryone J Kuss, PhD, FRCPA, FRACP, MBBS, John F Seymour, MD, FRACP

Blood (2010) 116 (21): 699.

https://doi.org/10.1182/blood.V116.21.699.699

Published: 2010

Journal Articles

Anaemia In Nonagenarians: Incidence, Severity and Aetiology

Justine S Brady, Nenna van Bilsen, Ping Han, MD, PhD, FRACP, FRCPA, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2010) 116 (21): 5138.

https://doi.org/10.1182/blood.V116.21.5138.5138

Published: 2010

Journal Articles

The Hsp90 Inhibitor SNX7081 Restores the Fludarabine Sensitivity of Chronic Lymphocytic Leukemia (CLL) Cells Harbouring Mutations of ATM or TP53

O. Giles Best, BSc, PhD, Stephen P Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2010) 116 (21): 2473.

https://doi.org/10.1182/blood.V116.21.2473.2473

Published: 2010

Journal Articles

Monoclonal B-Lymphocytosis: Analysis of the Incidence, Demographics, Nature and Subclassification in 414 Patients

Christopher S. Mulligan, Miriam E. Thomas, Stephen P. Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2008) 112 (11): 3129.

https://doi.org/10.1182/blood.V112.11.3129.3129

Published: 2008

Journal Articles

Immunoglobulin G (IgG) Subclasses in Chronic Lymphocytic Leukaemia

Jane A. Freeman, MBBS, MSc, Cecily J. Forsyth, MB, BS, FRACP, FRCPA, Naomi J. Mackinlay, MB, BS, FRACP, FRCPA, Ping Han, MD, PhD, Stephen P. Mulligan, MBBS, PhD, FRACP, FRCPA

Blood (2008) 112 (11): 4180.

https://doi.org/10.1182/blood.V112.11.4180.4180

Published: 2008

NARROW

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

MAPK-Erk1/2 Pathway Activation and Survival Of Chronic Lymphocytic Leukemia (CLL) Cells Is Induced By In Vitro Modeling Of The Tumor Microenvironment and Can Be Effectively Inhibited Using The MEK1 Inhibitor MEK162

Genomic Profiling In Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (ALLG CLL5 OFOCIR trial) As Initial Treatment Of Chronic Lymphocytic Leukemia (CLL)

The Prevalence of Monoclonal B-Lymphocytosis in Individuals Aged 90 to >100 Years Is 10% with More Non-CLL Than CLL-Like Clones

Inhibition of Mitogen Activated Protein Kinase Kinase (MEK1) Is Effective Against CLL Cells Cultured in Media Alone or in a Supportive Microenvironment and Is Synergistic with Fludarabine in a Mechanism That Involves Decreased Levels of Reactive Oxygen Species and MCL-1 Protein

Anaemia In Nonagenarians: Incidence, Severity and Aetiology

The Hsp90 Inhibitor SNX7081 Restores the Fludarabine Sensitivity of Chronic Lymphocytic Leukemia (CLL) Cells Harbouring Mutations of ATM or TP53

Monoclonal B-Lymphocytosis: Analysis of the Incidence, Demographics, Nature and Subclassification in 414 Patients

Immunoglobulin G (IgG) Subclasses in Chronic Lymphocytic Leukaemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only